Skip to content

The Burn Glove Trial - Hand Burn Dressing Pilot

The Burn Glove Trial-A Randomized Controlled Trial of Dressings for Partial Thickness Hand Burns

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02318056
Enrollment
0
Registered
2014-12-17
Start date
2015-12-31
Completion date
2016-07-31
Last updated
2016-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns

Keywords

hand, burns, thermal, dressing, Aquacel®, Mepilex® Transfer Ag, Xeroform®, Bacitracin®, partial thickness, epithelialization, wound healing, scar, scarring

Brief summary

Specific Aim 1: To determine if one of three burn dressings provides a less painful healing experience for partial thickness hand. Specific Aim 2: To evaluate if one of three dressings provides greater functionality during and after healing of partial thickness hand burns. Specific Aim 3: To determine if one of three burn dressings promotes aesthetically superior healing results for partial thickness hand burns.

Detailed description

Various products are on the market and available for use on partial thickness burns to the hand/s. Our current institutional standard of care is to use Xeroform Gauze (Coviden, Mansfield, MA) and Bacitracin Ointment (Fougera, Melville, NY) to promote a moist antibacterial healing environment with the ability to monitor the healing progress daily. However, silver (AG) based dressings that employ nanocrystalline technology with hydrofiber (Aquacel AG burn; ConvaTec, Princeton, NJ) or soft silicone foam (Mepilex AG ; Molnlycke Health Care, Dunstable, United Kingdom) have been well accepted as alternative dressing solutions. These dressings have longer interval times between changes, leading to a reported increase in patient comfort, diminished skin shearing/stripping, and rapid re-epithelialization. Given the anatomic intricacies, partial thickness burns to the hand present a challenge in dressing selection. Recently, ConvaTec unveiled the Aquacel AG Burn Glove for use on partial thickness hand burns. In line with this idea, our institution has now begun to fashion a novel burn glove out of Mepilex Transfer AG with good success. To date there are no known studies that compare Xeroform/Bacitracin, Aquacel AG burn glove or Mepilex Transfer AG dressing. The goal of this study is to compare these three burn dressings used to treat partial-thickness hand burns and their impact on pain, function, and aesthetic outcomes. We will also explore psychosocial issues related to hand burn dressing changes.

Interventions

OTHERAquacel® Ag Burn Glove

burn dressing

burn dressing

DRUGantibiotic

antibiotic burn dressing

Sponsors

Southern Illinois University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients presenting at Memorial Medical or Southern Illinois University (SIU) Health Care * Patients with partial-thickness burn injuries to the dorsum and/or palm of the hand/s that exceeds ½% total body surface area (TBSA) for at least one hand. * \< 10% TBSA 2nd and 3rd degree burn injuries * Initial clinical presentation \< 5 days post burn injury

Exclusion criteria

* \< ½ % TBSA involving the hand * \> 10%TBSA burn injuries * \> 60 years of age * \< 8 years of age * Patients (or parents of minors) without cognitive capacity to comprehend informed consent * Presentation \> 5 days post-burn injury event * Pregnant women * Full thickness/3rd degree burns to the dorsal and/or palmer hand/s * Exposed vital structures (tendons, nerves, bone, vessels) * Uncontrolled Type II Diabetes * Type I Diabetes * History of Chronic Obstructive Pulmonary Disease * Have a known allergy to silver products * Signs of infection on initial clinical presentation (presence of purulent drainage, significant cellulitis, and/or fever) * Smoke/inhalation injuries requiring ventilation * Critically ill patients requiring intensive care

Design outcomes

Primary

MeasureTime frameDescription
painbaseline to 6 months post-burn injurypain as measured by the Patient and Provider Scar Assessment Scale

Secondary

MeasureTime frameDescription
painbaseline to 6 months post-burn injurypain as measured by the Michigan Hand Outcomes Questionnaire (MHQ)
functionalitybaseline to 6 months post-burn injuryfunctionality as measured by the Michigan Hand Outcomes Questionnaire (MHQ)
aesthetic appearancebaseline to 6 months post-burn injuryscar formation and aesthetic appearance measured using the Vancouver Scar Scale

Other

MeasureTime frameDescription
quality of lifebaseline to 6 months post-burn injuryquality of life measured by the psychosocial scales: Burn Specific Health Scale (BSHS)
resiliencebaseline to 6 months post-burn injuryresilience measured by the Connor-Davidson Resilience Scale (CD-RISC)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026